The molecular biology of prostate cancer: current understanding and clinical implications

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Prostate Cancer and Prostatic Diseases

• Publication date

  2017-12-27

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/s41391-017-0023-8PMID 29282359
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate cancer.

  2019cited by this paper
• Prostate Cancer

  2018influential reference
• Immunotherapy and gene therapy in prostate cancer treatment

  2017cited by this paper
• Expending Role of Microsatellite Instability in Diagnosis and Treatment of Colorectal Cancers

  2017cited by this paper
• PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform.

  2017cited by this paper
• ETS (E26 transformation-specific) up-regulation of the transcriptional co-activator TAZ promotes cell migration and metastasis in prostate cancer

  2017cited by this paper
• miRNAs associated with prostate cancer risk and progression

  2017cited by this paper
• Evolving adoptive cellular therapies in urological malignancies.

  2017cited by this paper
• Racial disparities in prostate cancer: a molecular perspective.

  2017cited by this paper
• Clinical development of immunotherapy for prostate cancer

  2017cited by this paper
• Meta-analysis of the role of IL-6 rs1800795 polymorphism in the susceptibility to prostate cancer

  2017cited by this paper
• Potential Value of miR-221/222 as Diagnostic, Prognostic, and Therapeutic Biomarkers for Diseases

  2017cited by this paper
• miRNAs as novel biomarkers in the management of prostate cancer

  2017cited by this paper
• RGS12 Is a Novel Tumor-Suppressor Gene in African American Prostate Cancer That Represses AKT and MNX1 Expression.

  2017cited by this paper
• Diet-induced alteration of fatty acid synthase in prostate cancer progression

  2016cited by this paper
• MNX1 Is Oncogenically Upregulated in African-American Prostate Cancer.

  2016cited by this paper
• Prostate Cancer in African American Men: The Effect of Androgens and microRNAs on Epidermal Growth Factor Signaling

  2016cited by this paper
• Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer.

  2016influential reference
• The oncogene ERG: a key factor in prostate cancer

  2016cited by this paper
• The molecular and cellular origin of human prostate cancer.

  2016influential reference
• GSTP1 Methylation and Protein Expression in Prostate Cancer: Diagnostic Implications

  2016cited by this paper
• A Perspective of Immunotherapy for Prostate Cancer

  2016cited by this paper
• TET2 binds the androgen receptor and loss is associated with prostate cancer

  2016cited by this paper
• Novel biomarkers for the detection of prostate cancer

  2016cited by this paper
• Human DNA polymerase α interacts with mismatch repair proteins MSH2 and MSH6

  2016cited by this paper
• Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.

  2016cited by this paper
• Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer.

  2016cited by this paper
• DAB2IP regulates EMT and metastasis of prostate cancer through targeting PROX1 transcription and destabilizing HIF1α protein.

  2016cited by this paper
• Prostate cancer markers: An update.

  2016cited by this paper
• Prostate cancer

  2016cited by this paper
• DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.

  2015cited by this paper
• Development of PROSTVAC immunotherapy in prostate cancer.

  2015influential reference
• Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival

  2015cited by this paper
• The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone.

  2015influential reference
• Scavenger Receptors: Emerging Roles in Cancer Biology and Immunology.

  2015cited by this paper
• New insights into the mechanism of DNA mismatch repair

  2015cited by this paper
• Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer

  2015cited by this paper
• Erratum: Increased fatty acid synthase expression in prostate biopsy cores predicts higher Gleason score in radical prostatectomy specimen

  2015cited by this paper
• Androgen receptor: structure, role in prostate cancer and drug discovery

  2014influential reference
• Complex MSH2 and MSH6 mutations in hypermutated microsatellite unstable advanced prostate cancer

  2014cited by this paper
• TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers

  2014cited by this paper
• The Mitogen-activated Protein (MAP) Kinases p38 and Extracellular Signal-regulated Kinase (ERK) Are Involved in Hepatocyte-mediated Phenotypic Switching in Prostate Cancer Cells*

  2014influential reference
• ETS fusion genes in prostate cancer.

  2014cited by this paper
• The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

  2014cited by this paper
• Elucidating immunologic mechanisms of PROSTVAC cancer immunotherapy

  2014influential reference
• Down-Regulation of mir-221 and mir-222 Restrain Prostate Cancer Cell Proliferation and Migration That Is Partly Mediated by Activation of SIRT1

  2014cited by this paper
• Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.

  2014cited by this paper
• Emerging players in prostate cancer: long non-coding RNAs.

  2014cited by this paper
• Long noncoding RNAs and prostate carcinogenesis: the missing 'linc'?

  2014cited by this paper
• Identification of a long non-coding RNA as a novel biomarker and potential therapeutic target for metastatic prostate cancer

  2014cited by this paper
• The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex

  2013cited by this paper
• Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer.

  2013cited by this paper
• Genetic polymorphism and prostate cancer aggressiveness: A case‐only study of 1,536 GWAS and candidate SNPs in African‐Americans and European‐Americans

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Gene-engineered T cells for cancer therapy

  2013cited by this paper
• Profiling serum HER-2/NEU in prostate cancer.

  2013cited by this paper
• Androgen Receptor-Target Genes in African American Prostate Cancer Disparities

  2013cited by this paper
• Urinary biomarkers for prostate cancer: a review.

  2013cited by this paper
• Increased expression of EphA1 protein in prostate cancers correlates with high Gleason score.

  2013cited by this paper
• A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer.

  2013cited by this paper
• Somatic Alterations Contributing to Metastasis of a Castration‐Resistant Prostate Cancer

  2013cited by this paper
• The complexity of prostate cancer: genomic alterations and heterogeneity

  2012cited by this paper
• KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer

  2012cited by this paper
• Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.

  2012cited by this paper
• Germline mutations in HOXB13 and prostate-cancer risk.

  2012cited by this paper
• KAI1 suppresses HIF-1α and VEGF expression by blocking CDCP1-enhanced Src activation in prostate cancer

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• KLF6 loss of function in human prostate cancer progression is implicated in resistance to androgen deprivation.

  2012cited by this paper
• The role of BRCA1 and BRCA2 in prostate cancer.

  2012cited by this paper
• TGF-β mediated DNA methylation in prostate cancer

  2012cited by this paper
• PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling

  2012cited by this paper
• p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3

  2012cited by this paper
• MTHFR polymorphism and the risk of prostate cancer: a meta-analysis of case–control studies

  2012cited by this paper
• miR-21: an oncomir on strike in prostate cancer

  2010cited by this paper
• Current management of castrate-resistant prostate cancer.

  2010cited by this paper
• Genome-wide association study identifies five new susceptibility loci for prostate cancer in the Japanese population

  2010cited by this paper
• Identification of Differentially Methylated Genes in Normal Prostate Tissues from African American and Caucasian Men

  2010cited by this paper
• Association of socioeconomic status with inflammation markers in black and white men and women in the Coronary Artery Risk Development in Young Adults (CARDIA) study.

  2009cited by this paper
• Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

  2009cited by this paper
• Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility

  2009cited by this paper
• ETS rearrangements and prostate cancer initiation

  2009cited by this paper
• Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer

  2009cited by this paper
• Identification of a new prostate cancer susceptibility locus on chromosome 8q24

  2009cited by this paper
• Multiple loci on 8q24 associated with prostate cancer susceptibility

  2009cited by this paper
• ETS rearrangements and prostate cancer initiation

  2009cited by this paper
• Germ-Line Mutations in Mismatch Repair Genes Associated with Prostate Cancer

  2009cited by this paper
• Role of the TMPRSS2-ERG gene fusion in prostate cancer.

  2008cited by this paper
• Pathogenesis of prostate cancer: lessons from basic research.

  2008influential reference
• Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer

  2008cited by this paper
• Multiple newly identified loci associated with prostate cancer susceptibility

  2008cited by this paper
• Cumulative association of five genetic variants with prostate cancer.

  2008cited by this paper
• Multiple loci identified in a genome-wide association study of prostate cancer

  2008cited by this paper
• Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP.

  2007cited by this paper
• Genome-wide association study of prostate cancer identifies a second risk locus at 8q24

  2007cited by this paper
• Inflammation in prostate carcinogenesis

  2007cited by this paper
• Genome-wide association study identifies novel breast cancer susceptibility loci

  2007cited by this paper
• Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24

  2007cited by this paper
• Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes

  2007cited by this paper
• Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Yeager M, Orr N, Hayes RB, Jacobs KB, Kraft

  2007cited by this paper
• Multiple regions within 8q24 independently affect risk for prostate cancer

  2007cited by this paper

• RAB40C regulates SNX9 stability via the ubiquitin-proteasome system and modulates the Hippo signaling pathway of prostate adenocarcinoma

  2026cites this paper
• Precision Therapy for Prostate Cancer: Advancements in Polymeric Nanocarrier Systems.

  2025cites this paper
• PROTAC technology for prostate cancer treatment.

  2025cites this paper
• Computational study for the identification of phytochemical from Acacia hydaspica as potent inhibitor for addressing KRAS-related non-small cell lung cancer: Perspectives on ligand-based drug discovery

  2025cites this paper
• Towards personalized prostate cancer treatment with docetaxel in indonesia: a pharmacogenomics perspective

  2025cites this paper
• Mutational and low-coverage whole genome sequencing identifies actionable DNA repair alterations in prostate cancer plasma DNA

  2025cites this paper
• Exploring Latent Prostate Cancer: A Forensic Autopsy Study in South India

  2025cites this paper
• TGF-β3 promotes vascular normalization of prostate cancer to potentiate immunotherapy and chemotherapy

  2025cites this paper
• WTAP-mediated m6A modification of ARG2 mRNA Inhibits Its expression and drives prostate cancer malignant progression.

  2025cites this paper
• Green mediation, characterization, and treatment of prostate cancer by the Lawsonia inermis-based silver nanoparticles

  2025cites this paper
• Clinical, Imaging, and Technical Factors Associated with Successful Genomic Profiling of Bone Biopsy Tissue in Prostate Cancer.

  2024cites this paper
• Transcriptomic response of prostate cancer cells to carbon ion and photon irradiation with focus on androgen receptor and TP53 signaling

  2024cites this paper
• Patient-Derived Conditionally Reprogrammed Cells in Prostate Cancer Research

  2024cites this paper
• Analyzing the Mutational Landscape of Prostate Cancer Susceptibility Genes through Next-Generation Sequencing (NGS) Analysis

  2024cites this paper
• Highlighting function of Wnt signalling in urological cancers: Molecular interactions, therapeutic strategies, and (nano)strategies

  2024cites this paper
• Identification and validation of diagnostic and prognostic biomarkers in prostate cancer based on WGCNA

  2024cites this paper
• Immunotherapeutic Treatment for Metastatic Prostate Cancer: A Review of Recent Clinical Trials

  2024cites this paper
• Silver Nanoparticles (AgNPs) Uptake by Caveolae-Dependent Endocytosis is Responsible for Their Selective Effect Towards Castration Resistant Prostate Cancer

  2024cites this paper
• Molecular Activities and Mechanisms of Action of Substances and Molecules from Medicinal Plants from Sub-Saharan Africa on Prostate and Cervical Cancer Cells.

  2024cites this paper
• Age-Related Anatomical Variations in the Prostate Gland, Implications for Urological Health and Disease Progression

  2023cites this paper
• PROTACs in the Management of Prostate Cancer

  2023cites this paper
• Metallic Cation-Mediated Entrapment of Nucleic Acids on Mesoporous Silica Surface: Application in Castration-Resistant Prostate Cancer

  2023cites this paper
• Novel dual-targeting inhibitors of NSD2 and HDAC2 for the treatment of liver cancer: structure-based virtual screening, molecular dynamics simulation, and in vitro and in vivo biological activity evaluations

  2023cites this paper
• Dose outside of the prostate is associated with improved outcomes for high-risk prostate cancer patients treated with brachytherapy boost

  2023cites this paper
• MicroRNAs as biomarkers for early diagnosis, targeting and prognosis of prostate cancer.

  2023cites this paper
• Investigating Metformin & Syrosingopine's Synthetic Lethality in PC3 & THP-1 Cancer Cell Lines

  2022influential citation
• Glucose-Functionalized Silver Nanoparticles as a Potential New Therapy Agent Targeting Hormone-Resistant Prostate Cancer cells

  2022cites this paper
• Clinical implications of homologous recombination repair mutations in prostate cancer

  2022cites this paper
• Prostate Surface Distension and Tumor Texture Descriptors From Pre-Treatment MRI Are Associated With Biochemical Recurrence Following Radical Prostatectomy: Preliminary Findings

  2022cites this paper
• Detection of disease‐causing mutations in prostate cancer by NGS sequencing

  2022cites this paper
• SLC4A4 promotes prostate cancer progression in vivo and in vitro via AKT-mediated signalling pathway

  2022cites this paper
• What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review (Part 6): Correlation of PD-L1 Expression with the Status of Mismatch Repair System, BRCA, PTEN, and Other Genes

  2022influential citation
• Role of Precision Oncology in Type II Endometrial and Prostate Cancers in the African Population: Global Cancer Genomics Disparities

  2022cites this paper
• Prostate cancer histopathology using label-free multispectral deep-UV microscopy quantifies phenotypes of tumor aggressiveness and enables multiple diagnostic virtual stains

  2021cites this paper
• tRNALys-Derived Fragment Alleviates Cisplatin-Induced Apoptosis in Prostate Cancer Cells

  2021cites this paper
• Identification of RNA-binding protein SNRPA1 for prognosis in prostate cancer

  2021cites this paper
• Genome-wide Expression Analysis Identifies the Association between SEC14L2 and Castration-resistant Prostate Cancer Survival

  2021cites this paper
• The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance

  2021cites this paper
• Single nucleotide polymorphisms (SNPs) in prostate cancer: its implications in diagnostics and therapeutics.

  2021cites this paper
• Unravelling the Molecular Mechanisms of Prostate Cancer Evolution from Genotype to Phenotype.

  2021cites this paper
• Prostate cancer histopathology with label-free multispectral deep UV microscopy quantifies phenotypes of tumor grade and aggressiveness

  2021cites this paper
• Biopolymer and Biomaterial Conjugated Iron Oxide Nanomaterials as Prostate Cancer Theranostic Agents: A Comprehensive Review

  2021cites this paper
• Fusion Protein Vaccine Based on Ag85B and STEAP1 Induces a Protective Immune Response against Prostate Cancer

  2021cites this paper
• Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer

  2021cites this paper
• Microbiota and prostate cancer.

  2021cites this paper
• Targeting the Lnc-OPHN1-5/androgen receptor/hnRNPA1 complex increases Enzalutamide sensitivity to better suppress prostate cancer progression

  2021cites this paper
• Prostatakrebs – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung

  2021cites this paper
• Cáncer de próstata de inicio temprano. ¿Una nueva entidad?

  2021cites this paper
• SNAP25 is a potential prognostic biomarker for prostate cancer

  2021cites this paper
• What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 5: Epigenetic Regulation of PD-L1

  2021influential citation
• What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment

  2021cites this paper
• Prevalence and Demographic Characteristics of Prostate Cancer Patients in Colombia: data from the National Health Registry from 2015 to 2019

  2021cites this paper
• Epidemiological Profile of Prostate Cancer in Brazil

  2021cites this paper
• Arginine and Arginases Modulate Metabolism, Tumor Microenvironment and Prostate Cancer Progression

  2021cites this paper
• High resolution crystal structure of a KRAS promoter G-quadruplex reveals a dimer with extensive poly-A π-stacking interactions for small-molecule recognition

  2020cites this paper
• Development of Novel 111-In-Labelled DOTA Urotensin II Analogues for Targeting the UT Receptor Overexpressed in Solid Tumours

  2020cites this paper
• Targeting USP1‐dependent KDM4A protein stability as a potential prostate cancer therapy

  2020cites this paper
• The Impact of HMGB1 Polymorphisms on Prostate Cancer Progression and Clinicopathological Characteristics

  2020cites this paper
• Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers

  2020cites this paper
• Loss of EGR3 is an independent risk factor for metastatic progression in prostate cancer

  2020cites this paper
• Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness

  2020cites this paper
• Androgen receptor variant-driven prostate cancer II: advances in clinical investigation

  2020cites this paper
• Urupocidin C: a new marine guanidine alkaloid which selectively kills prostate cancer cells via mitochondria targeting

  2020cites this paper
• Broadening Drug Design and Targets to Tumor Microenvironment? Cancer-Associated Fibroblast Marker Expression in Cancers and Relevance for Survival Outcomes

  2020cites this paper
• PAWI-2: A novel inhibitor for eradication of cancer

  2020influential citation
• Next-Generation Sequencing in Prostate Cancer

  2020cites this paper
• The role of protein tyrosine phosphatases in prostate cancer biology.

  2019cites this paper
• Prostatic Acinar Adenocarcinoma

  2019cites this paper
• Targeting the USP1 dependent KDM4A protein stability as a potential prostate cancer therapy

  2019cites this paper
• Genomic analysis of Korean patients with advanced prostate cancer by use of a comprehensive next-generation sequencing panel and low-coverage, whole-genome sequencing

  2019cites this paper
• Genetic variants of PARP4 gene and PARP4P2 pseudogene in patients with multiple primary tumors including thyroid cancer.

  2019cites this paper
• Activator of G protein signaling 3 modulates prostate tumor development and progression.

  2019cites this paper
• Differentially Expressed Genes and Molecular Pathways in an Autochthonous Mouse Prostate Cancer Model

  2019cites this paper
• A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer

  2019cites this paper
• Pathway Analysis of Genes Identified through Post-GWAS to Underpin Prostate Cancer Aetiology

  2019cites this paper
• MicroRNA biogenesis, gene silencing mechanisms and role in breast, ovarian and prostate cancer.

  2019cites this paper
• DNA methylation signatures of Prostate Cancer in peripheral T-cells

  2018cites this paper
• Clinical perspectives of PSMA PET/MRI for prostate cancer

  2018influential citation
• Investigation into the metabolic effect of sarcosine on prostate cancer

  2018cites this paper
• Prostate Cancer Screening: Outcomes and Risk Prediction

  2018cites this paper